CURE3d
Favorable Initial Results in Phase 1 Trial for PD-L1 Resistant Tumors
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors
Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 ...
Taiwan News4d
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
About Dupixent Dupixent is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD. Dupixent is intended for injection under the skin (subcutaneous ...
Sensei Biotherapeutics announces initial results from solnerstotug trial portion
Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a ...
The Manila Times4d
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?
We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are ...